,y-scintillation counter . The F(ab') 2 fragment was derived by digestion with pepsine from the purified mAb as described by Parham (9) . The F(ab') 2 piece appeared in SDS-PAGE as an homogeneous band of^-100 kD. Other mAbs used in these studies were: Leu 7 (anti HNK-1) and Leu 11 (anti-CD16) (purchased from Becton Dickinson & Co, Sunnyvale, CA) and the previously described (10) MAR 21 (anti-CD7) and J90 (anti-LFA-1) mAbs.
Isolation of Subpopulations of Peripheral Blood . Human PBMC and granulocytes were isolated from healthy volunteer donors by Ficoll-Hypaque (F/H) density gradient centrifugation . E+ and E-cell fractions were obtained by rosetting PBMC with neuraminidasetreated sheep erythrocytes (11) . The two fractions were separated by a F/H gradient centrifugation . Monocytes were isolated by adherence on plastic Petri dishes . After extensive washes to remove nonadherent cells, the adherent cells were detached by incubation in ice for 2 h. B cell-enriched population was obtained by removing E-rosetting cells from a spleen cell suspension . The residual population contained >95% of sIg + cells. Platelets were isolated after F/H density gradient centrifugation of heparinized blood . LAK-1 + and LAK-1 -cells were sorted with a FACS (FACS II ; Becton Dickinson Immunocytometry Systems, Mountain View, CA) after indirect immunofluorescence staining of PBMC with the LAK-1 mAb (12) .
Indirect Immunof uorescence and Flow Cytofluorometric Analysis . Cells were stained with hybridoma supernatants (25 I.1/10 5 cells) followed by fluoresceinated goat F(ab') 2 antimouse Ig as previously described (12) . The samples were analyzed on a flow cytometer gated to exclude nonviable cells. Results are expressed as arbitrarily normalized fluorescence histograms, i.e., number of cells vs. fluorescence intensity .
LAK Activation and Cytotoxicity Assay. PBMC at 106/ml concentration were cultured at 37°C for 3 d in complete medium (RPMI containing 20% FCS) supplemented with 50 U/ml of rIL-2 (Cetus Corp., Emeryville, CA) . The cells were then harvested, washed twice, and used as effector cells for lysis of cryopreserved fresh melanoma tumor cells . Lysis was tested in a 4-h "Cr-release assay at the E/T ratio of 10:1 . The results are expressed in percent specific lysis (13) . In the inhibition experiments, effector cells were preincubated with graded amounts (0.01-100,ug/ml) of either purified anti LAK-1 mAb or of the F(ab')2 fragment of the same antibody, for 1 h at room temperature (RT), washed twice, and used in the "Cr-release assay. As a control we used anti-CD7 or anti-LFA-1 mAbs.
Characterization of the LAK-I Antigen . JA3 cells (8) were surface-labeled with '211 using lactoperoxidase/glucose oxidase-catalyzed iodination (14) . Cells were then washed five times in cold RPMI 1640, twice in PBS, and lysed in 10 mM Tris-buffered saline (pH 7.5) containing 1% NP-40, 1 mg/ml BSA, and 0.1 mM PMSF, for 20 min at 4°C . After spinning at 100,000 g, the supernatant was then immunoprecipitated as follows . Supernatants were dialyzed with PBS containing 0 .05% NP-40 and 0.1 mM PMSF and precleared three times with 100 ul of packed protein A-Sepharose beads for 2 h under rotation . Aliquots (200 ul) were then incubated for 2 h with 20 JAI of a 1 :10 dilution of anti-LAK-1 mAb. 20 yl of packed protein A-Sepharose beads were then added and samples were incubated for 4 h at 4°C . The immunoprecipitate was eluted from protein A-Sepharose by boiling for 2 min in 5% SDS in the presence or absence of 5% 2-ME and analyzed on 8% discontinuous SDS-polyacrylamide gels (15) .
Results and Discussion
To produce mAbs directed against surface molecules expressed by human LAK cells, DBA/2 mice were immunized with the clone SF16 derived as previously described (13) , which displays a strong cytolytic activity against a variety of fresh or cultured human tumor cells (13) . The surface phenotype of the SF-16 clone as assessed by immunofluorescence and FACS analysis was CD3 -, CD28-(Tp44), CD4 -, CD8 -, CD2 +, CD7 +, HLA-DR', HNK-1 -. This clone, which was derived from peripheral blood CD16+ cells, was weakly stained by anti-CD 16 (Leu-11) mAb. After fusion, hybridoma SN were first screened for LGL . As shown in Fig . 2 , virtually all the NK activity exhibited by fresh PBMC was confined to the LAK-l + fraction. In addition, when LAK-1 + and LAK-1 -cells were cultured with rIL-2 and analyzed at different time intervals for their ability to lyse fresh melanoma target cells (Fig. 2) , LAK activity was clearly confined to the LAK-l + population . The cytolytic activity of this population was higher than that generated in unfractionated PBMC . Note also that unlike PBMC, LAK-l + cells maintained a strong LAK activity for a relatively long culture interval . These data indicate that the majority of the cells belonging to the LAK precursor pool express the LAK-1 surface antigen . Furthermore, >90% of the LAK-l + cells remained positive after 7 d of culture in rIL-2 ( Fig.  3) , whereas the LAK-1 -population did not express LAK-1 antigen after culture under the same conditions (not shown) .
We next investigated whether LAK-1 was expressed on the LAK cells contained in unfractionated PBMC after culture in rIL-2. To this end, PBMC populations that had been cultured for 3 d in rIL-2 were separated by FACS A and B) . The cytolytic activity against the NKresistant fresh melanoma cells and against the NK-sensitive K562 cell line was tested either 12 h after separation (day 0) or at days 3 and 7. Experiments reported in C and D were performed after culturing unfractionated PBMC in 50 U/ml rIL-2 followed by sorting of LAK-1' and LAK-1 -populations . The two subsets, as well as the unfractionated populations, were recultured in rIL-2 and then assessed for cytolytic activity either 12 h after separation (day 3) or at day 7 and 14 . into LAK-1 + and LAK-1 -subsets (FACS analysis showed a clear bimodal distribution of LAK-I expression on these cells) and were analyzed for their cytolytic activity against melanoma cells. Sorted cells were extensively washed and cultured for -12 h before performing the cytolytic assay. Fig. 2 , C and D, show that cytolytic cells were confined to the LAK-I' cell fraction . Taken together, these data suggest that the expression of LAK-1 antigen represents a stable characteristic of LAK cells. In another group of experiments, FACS-sorted peripheral blood LAK-1 + cells were cultured for up to 3 wk in rIL-2 and analyzed at different culture intervals for the expression of LAK-1 antigen and other surface antigens expressed by LGL, such as CD16 and HNK-1 . Whereas the expression of CD 16 ( Fig . 3) and HNK-1 (not shown) decreased progressively during culture, LAK-1 antigen was still brightly expressed on the majority of cells even after 20 d of culture (Fig. 3) . In another series of experiments we studied whether LAK-I was involved in the cytolytic activity of LAK effector cells. As shown in Table 1 , the LAK activity of PBMC cultured for 3 d in rIL-2 was inhibited by preincubation of the effector cells with anti-LAK-1 or anti-LFA-1 mAb. On the other hand, an mAb directed to the CD7 antigen (which is expressed also by all LAK cell clones studied so far) (12) had no inhibitory activity . Similarly, LAK activity was not inhibited by mAbs directed to HNK-I or CD 16 antigens (data not shown) . Unlike anti-LFA-I mAb, however, anti-LAK-1 mAb did not inhibit the cytolytic activity of alloreactive T cell populations derived from mixed lymphocyte cultures (data not shown) . To determine the concentration of anti-LAK-1 mAb needed for inhibition of lysis of fresh tumor targets, graded amounts either of purified mAb or of the F(ab') 2 fragment were used in the inhibition assay . As shown in Fig. 4 , maximal inhibition was observed with 10 ug/ml of both inhibitors.
Given the inhibitory activity of anti-LAK-1 mAb on LAK effector function, we next investigated whether the mAb also inhibited the NK activity . Anti-LAK-I mAb did not significantly block lysis of the NK-sensitive K562 target cells either by freshly derived PBMC or by lymphocytes cultured for 3 d in rIL-2 (<20% inhibition). It is noteworthy, however, that in parallel experiments, anti-LFA-1 mAb was also in most instances unable to efficiently block lysis of K562 target cells (not shown) . 
